Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇨🇦CA · Life Sciences#1355K to 30K
- 🇸🇦SA · Life Sciences#138500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
3.9K to 23K🎙 Weekly cadence·24 episodes·Long inactive - Monthly Reach
Unique listeners across all episodes (30 days)
5.5K to 33K🇨🇦91%🇸🇦9% - Active Followers
Loyal subscribers who consistently listen
1.6K to 9.9K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Convergence, collaboration and commercialization in cell and gene therapies
May 15, 2025
32m 38s
Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector
Apr 15, 2025
38m 18s
Navigating commercialization: Regional hubs, global solutions
Mar 15, 2025
23m 09s
Enabling patient access to cell and gene therapies
Feb 15, 2025
28m 20s
Unapproved stem cell therapies: Risks, realities and responsibilities
Jan 15, 2025
35m 30s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/15/25 |  Convergence, collaboration and commercialization in cell and gene therapies | Featuring: Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of Toronto Audrey Greenberg, MBA, CEO & Founder, AG Capital Advisors *** In this engaging episode of “Commercializing Living Therapies with CCRM,” we sit down with two leaders in the life sciences field: Molly Shoichet, a biomedical engineer and University Professor at the University of Toronto, and Audrey Greenberg, Founder and M... | 32m 38s | ||||||
| 4/15/25 |  Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector | Reni Benjamin, Managing Director, Healthcare Equity Research at Citizens Brock Reeve, CEO and Co-founder, Eos BioInnovation *** In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks with Reni Benjamin and Brock Reeve about the current financial landscape for cell and gene therapies (CGTs). They explore the unique dynamics companies face, from securing funding to navigating regulatory hurdles, and discuss how investors assess risks and opportunities in the fiel... | 38m 18s | ||||||
| 3/15/25 |  Navigating commercialization: Regional hubs, global solutions | Featuring: Silvio Tiziani, CEO, CCRM Australia Sarah Callens, CTO, CCRM Nordic *** In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM Nordic, explore the opportunities and challenges of commercializing regenerative medicines, including cell and gene therapies, in their respective regions. While scientific discoveries abound, barriers such as regulatory hurdles, funding gaps and infrastructure limitations can slow th... | 23m 09s | ||||||
| 2/15/25 |  Enabling patient access to cell and gene therapies | Featuring: Durhane Wong-Rieger, PhD, President and CEO, Canadian Organization for Rare Disorders Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult *** In this episode, we dive into the critical topic of enabling patient access to cell and gene therapies with two leaders in the field. Jacqueline Barry, an expert in the development and adoption of advanced therapies, shares her insights on the challenges involved with bringing innovative treatments to patients, from ... | 28m 20s | ||||||
| 1/15/25 |  Unapproved stem cell therapies: Risks, realities and responsibilities | Featuring: Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of Medicine Amy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina *** Unapproved stem cell therapies continue to be a significant concern in the regenerative medicine field. In this episode, Drs. Paul Knoepfler and Amy Zarzeczny discuss the issue. Listeners will hear the risks and implications of these treatments, and why they are not ... | 35m 30s | ||||||
| 12/15/24 |  Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies | Featuring: Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. *** We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners. In this episode, we explore how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. Our guests discu... | 34m 59s | ||||||
| 4/15/24 |  Expert insights for taking a cell or gene therapy company from vision to reality | Featuring: Jacki Jenuth, PhD, Partner and COO, Lumira Ventures Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM *** In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and Venture Development, CCRM. The conversation covers the essence of venture capital funding, from how VCs evaluate investment potential to cruci... | 26m 25s | ||||||
| 2/15/24 |  Regulators' strategies for managing the surge in cell and gene therapies | Featuring: Michael Rosu-Myles, PhD, Executive Director, Health Canada Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine *** Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by patients, regulators determine whether these innovative therapies move from the lab to market. In this interview, Michael Rosu-Myles, PhD, Execu... | 27m 35s | ||||||
| 1/15/24 |  How Creative Destruction Lab accelerates the advanced therapies industry | Featuring: Sonia Sennik, Executive Director, Creative Destruction Lab Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM *** In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize their discoveries. With a mission of enhancing the commercialization of science for the betterment of humankind, Creative Destruction Lab is... | 24m 23s | ||||||
| 12/15/23 |  The synergy solution: How public-private partnerships advance regenerative medicine | Featuring: Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Michael May, PhD, President and Chief Executive Officer, CCRM *** Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies alon... | 34m 43s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/15/23 |  Catalysts of change: Canada’s research hubs are shaping the future of biomanufacturing | Featuring: Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toronto *** The COVID-19 pandemic illuminated a need to scale up Canada’s biomanufacturing capacity. As a response, the Government of Cana... | 33m 24s | ||||||
| 10/15/23 |  From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine | Featuring: Mamatha Bhat MD, MSc, PhD, FRCPC Hepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health Network Associate Professor, Division of Gastroenterology & Hepatology Director, Clinician-Scientist Training Program (CSTP), Department of Medicine, University of Toronto Partnerships & Engagement Lead, Temerty Centre for AI in Research & Education in Medicine (T-CAIREM); Fac... | 33m 23s | ||||||
| 4/14/23 | Stuck in the sixties: The fight to fast-forward access to better cancer treatment | Featuring: Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who supported their children through cancer treatments. Listeners will hear their unflinching accounts of what the children went through, underlining the urgent need for access to innovative and less toxic treatments. Tom is the co-founder of the Emily Whitehead... | 27m 24s | ||||||
| 3/14/23 | CAR T therapies: Engineering immune cells to treat cancer | Featuring: Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine. Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine share their thoughts on which of these two approaches is likely to pull ahead in the years to come, while ac... | 31m 10s | ||||||
| 2/14/23 | Protecting the product of innovation: IP and commercialization in cell and gene therapies | Featuring: Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics In the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, guests outline how the regenerative medicine industry changed that, proving the belief to be outdated, with some innovation being better pro... | 34m 23s | ||||||
| 1/15/23 | Mentoring: making moves to maximize career growth | Featuring: Dr. Dolores Baksh, CEO of TAAV Biomanufacturing Solutions Susan Nichols, Chief Business Officer at ViroCell Biologics As the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emphasize the importance of nurturing a new workforce equipped with the skills to pivot and persevere—crucial qualities for the industry to grow. Join our guests as they discuss the significance of mentorship in the cell and gene therapy space, which mentorship programs ... | 27m 53s | ||||||
| 12/14/22 | Unlocking the potential of induced pluripotent stem cells | Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the biggest challenges that will need to be addressed to unlock the potential of induced pluripotent stem cells (iPSCs), from regulatory issues to quality assurance and safety. Listen to hear about the proactive approach CCRM takes with its iPSC Excellence Team. You’ll a... | 27m 31s | ||||||
| 11/14/22 | Training tomorrow’s talent: building the biomanufacturing workforce | Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL) Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovations Drs. Christine Allen and Qasim Rafiq offer insight on how to train and retain tomorrow’s cell and gene therapy (CGT) workforce in a very competitive space. We’ve witnessed an “explosion” of activity and they believe it’s up to industry to address the skills gap and to focus on t... | 23m 05s | ||||||
| 6/14/22 | You get what you pay for | How will Canada’s health care system pay for cell and gene therapy cures? Featuring: Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement, Gilead Sciences Canada Our guests tackle the complex question of how therapy developers working at the cutting edge of regenerative medicine can get reimbursed when they deliver on the promise of cures. How can patients on Prince... | 35m 21s | ||||||
| 5/14/22 | A busy intersection: Ethics and policy in cell and gene therapies | Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future. Featuring: Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University Siofradh McMahon, Director, Clinical Translation and Regulatory Affairs, CCRM Join guests for a discussion about the responsibilities of the regenerative medicine industry, exploring how ethic... | 35m 25s | ||||||
| 3/14/22 | The Future’s Synthetic | Looking to the future of synthetic biology in cell and gene therapies. Featuring: Dr. George Church, Professor of Genetics, Harvard Medical School Dr. Peter Zandstra C.M., Director and Professor, School of Biomedical Engineering, University of British Columbia Hear from Drs. Church and Zandstra about the promise of the emerging synthetic biology field, looking to the impact developments will have on cell and gene therapies. They discuss how the regenerative medicine ecosyste... | 25m 23s | ||||||
| 2/14/22 | Moving from A to B | Manufacturing and supply chain issues in cell and gene therapies. Featuring: Dr. Anthony Davies, Founder and CEO, Dark Horse Consulting Rob Jones, Vice President, Global Bioservices, Cryoport Systems It’s no secret that supply chain and manufacturing are crucial to the cell and gene therapy industry, but now the whole world seems to be paying attention. This sudden interest has made Anthony Davies and Rob Jones very popular at dinner parties! Join our guests an... | 31m 10s | ||||||
| 1/14/22 | Chaperoning innovation through the valley of death | The business of regenerative medicine and investment. Featuring: Dr. Cynthia Lavoie, President and Chief Investment Officer, CCRM Enterprises Geoff MacKay, President and CEO, AVROBIO Dr. Lavoie and Mr. MacKay share what brought them to regenerative medicine in the first place, why investors are bullish about the field, and which trends they have an eye on as they are looking to the future. Join our guests and CCRM’s host, Krista Lamb, as we unpack the business of rege... | 26m 32s | ||||||
| 12/14/21 |  The importance of educating the public about cell and gene therapies | How can the regenerative medicine community create broader societal awareness? Featuring: Dr. Janet Rossant, President and Scientific Director, Gairdner Foundation Dr. Phil Vanek, Chief Technology Officer, Gamma Biosciences Drs. Rossant and Vanek discuss public awareness of cell and gene therapies, the importance of improving it, and how confusing and misleading claims made about unapproved stem cell treatments hinder our sector’s public education efforts. Join our guests and CC... | 24m 43s | ||||||
Showing 24 of 24
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.